Monte Rosa Therapeutics (GLUE) Cash from Operations (2020 - 2026)

Monte Rosa Therapeutics' Cash from Operations history runs 7 years deep, the most recent figure standing at 37369000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations rose 17.86% year-over-year to 37369000.0 in Q1 2026; TTM through Mar 2026 was 14675000.0, a 142.33% decrease from a year earlier, with the FY2025 full-year figure at 22798000.0, down 154.29% from the prior year.
• Cash from Operations climbed to 37369000.0 in Q1 2026 per GLUE's latest filing, from 43014000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 128922000.0 in Q4 2024 and bottomed at 45492000.0 in Q1 2025.
• The 5-year median for Cash from Operations is 24706000.0 (2023), against an average of 9084647.06.
• Biggest YoY gain for Cash from Operations was 578.37% in 2025; the steepest drop was 133.36% in 2025.
• Year by year, Cash from Operations stood at 23961000.0 in 2022, then soared by 223.68% to 29634000.0 in 2023, then jumped by 335.05% to 128922000.0 in 2024, then tumbled by 133.36% to 43014000.0 in 2025, then advanced by 13.12% to 37369000.0 in 2026.
• Per Business Quant, the three latest GLUE Cash from Operations figures stand at 37369000.0 (Q1 2026), 43014000.0 (Q4 2025), and 100428000.0 (Q3 2025).